4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer
27 sept. 2022 16h10 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for...
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
20 sept. 2022 16h15 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for...
4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update
11 août 2022 16h03 HE
|
4D Molecular Therapeutics, Inc.
- Five clinical-stage product candidates on track for multiple clinical data updates in 2023 - Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of...
4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences
02 juin 2022 16h02 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted...
4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates
12 mai 2022 16h01 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted...
4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference
05 mai 2022 16h02 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a a clinical-stage biotherapeutics company harnessing the power of directed evolution for...
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis
04 avr. 2022 16h02 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for...
4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights
28 mars 2022 16h02 HE
|
4D Molecular Therapeutics, Inc.
Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating preliminary...
4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company’s Board of Directors
22 févr. 2022 16h02 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
11 févr. 2022 16h03 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted...